What is the approximate latest market price of a bottle of mitotane?

Mitotane is a rare tumor-specific drug. Its main indication is Adrenocortical Carcinoma (ACC). It is especially suitable for patients who are unresectable, have a high risk of postoperative recurrence, or have distant metastasis. Clinically, mitotane is recommended as a postoperative adjuvant treatment for ACC to prolong recurrence-free survival and can also be used for control treatment of advanced cases. In addition, in functional ACC, mitotane can effectively relieve endocrine symptoms and improve patients' quality of life by reducing the secretion of adrenal hormones (such as cortisol or androgens). Although it is not used to treat other types of solid tumors, its mechanism has led to more exploration of targeted therapies and hormone-dependent tumors.

Regarding the market price of mitotane, although the domestic original drug has been imported through specialty drug channels, it has not yet been included in the national medical insurance catalog due to its short time on the market, and the price system has not yet been formally established. According to overseas market data, the original drug of mitotane is mainly produced by HRA Pharma. The specification is 500 mg × 100 tablets/bottle. It sells for about 9,000 yuan per bottle in European or Turkish pharmacies. The price fluctuates due to exchange rates and international logistics. There are also some generic drug versions on the market, such as the Lao version of mitotane, which has the same main ingredients as the original drug. However, due to differences in registration location and production costs, its price per bottle may be more than 2,000 yuan, making it an economical alternative for some patients.

It is worth noting that because mitotane is a rare disease drug, domestic supply still relies on imported channels, and patients’ purchasing channels are relatively limited, and they need to obtain it through specialty drug platforms or overseas drug purchases. Although the price is higher, from the perspective of treatment cost and improved prognosis, it is of great significance in delaying disease progression and reducing hormone-related complications.

Reference materials:https://go.drugbank.com/drugs/DB00648